Competitive based upon experience: Barrington James: Seeking a highly motivated and experienced Senior Scientist to join the Immuno-Oncology team of...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - PHARMABIZ.COM - A la Une - 19/Jun 00:00
iTeos, GSK initiate GALAXIES Lung─301 phase 3 study of belrestotug and dostarlimab in previously untreated, unresectable locally advanced/metastatic PD─L1 selected NSCLC
iTeos Therapeutics, Inc. (iTeos), a clinical─stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno─oncology therapeutics for patients, and its development
Articles similaires
Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism
mangaloremirror.com - 02/Jul 12:51
MIAMI, FL, July 02, 2024 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing...
Pompe Disease Clinical Trials Analysis 2024: Pipleine, Therapies, FDA Approvals, ROA, MOA and Companies by DelveInsight
mountaintoday.in - 05/Jul 07:24
Pompe Disease Clinical Trials Pompe Disease Companies are Spark Therapeutics, Amicus Therapeutics, Asklepios Biopharmaceutical, Audentes Therapeutics,...
Sirnaomics Announces Completion of STP707 Phase I Clinical Study with Strong Safety Profile and Disease Activity for the Treatment of Pancreatic Cancer Patients
drugs.com - 29/Jun 22:06
HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 28, 2024 Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or...
Cartesian Therapeutics doses first patient in phase 2 clinical trial of Descartes─08 to treat systematic lupus erythematosus
pharmabiz.com - 04/Jul 00:00
Cartesian Therapeutics, Inc, a clinical─stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, announced that the first...
PD-1 Non-Small Cell Lung Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight
mountaintoday.in - 26/Jun 19:16
DelveInsight’s, “PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Insight 2024” report provides comprehensive...
Syneos Health - USA: CRA II - Sponsor Dedicated - Oncology (Home-based, East Coast of US)
pharmiweb.com - 29/Jun 00:00
Competitive: Syneos Health - USA: Clinical Research Associate II Syneos Health® is a leading fully integrated biopharmaceutical solutions...
Amplity Health: Medical Science Liaison, Oncology (Metastatic Breast Cancer), Italy
pharmiweb.com - 28/Jun 00:00
Competitive: Amplity Health: Come join the true partner of global healthcare companies, Amplity Health. We continually challenge the boundaries of...
Amplity Health: Medical Science Liaison, Oncology (Metastatic Breast Cancer), Poland
pharmiweb.com - 28/Jun 00:00
Competitive: Amplity Health: Come join the true partner of global healthcare companies, Amplity Health. We continually challenge the boundaries of...
Syneos Health: CRA in Oncology - Sponsor dedicated
pharmiweb.com - 05/Jul 00:00
Competitive: Syneos Health: Clinical Research Associate in Oncology - Sponsor dedicated Syneos Health® is a leading fully integrated...
Les derniers communiqués
-
Aucun élément